An interventional study of MN Nutra GeLiPthin-1™ Dietary Supplement and Placebo in Overweight, Obesity and Weight Management, sponsored by MNnutra. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-26.
Sponsored by MNnutra · Not applicable, Interventional, and Treatment
This is a randomized, double-blind, placebo-controlled, decentralized clinical trial evaluating the effects of MN Nutra GeLiPthin-1™, a multi-ingredient dietary supplement, on body weight, BMI, waist circumference, appetite, satiety, and energy levels in overweight and obese adults over six weeks. A total of 170 generally healthy adults aged 18-65 years with a BMI of 27.0-35.0 kg/m² will be randomized 1:1 to receive either the active supplement or a matching placebo.
Participants will take three capsules orally twice daily for six weeks. All study activities are conducted remotely, including electronic consent, self-administered anthropometric measurements using a sponsor-provided Withings Scale and tape measure, and weekly online questionnaires via the Citruslabs digital study platform. The primary outcome is change in body weight from Baseline to Week 6.
3,776 studies on the registry are indexed under Overweight; 861 are open to participants now.
This study's planned enrollment of 170 is above the median of 73 across 3,267 interventional studies indexed under Overweight.
Browse Overweight studies →This is the only study on the registry with MNnutra as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Dietary Supplement: MN Nutra GeLiPthin-1™ Dietary Supplement
Dietary Supplement: Placebo
Participants will take three capsules orally twice daily for six weeks. All study activities are conducted remotely, including electronic consent, self-administered anthropometric measurements using a sponsor-provided Withings Scale and tape measure, and weekly online questionnaires via the Citruslabs digital study platform.
Participants receive matching placebo capsules containing microcrystalline cellulose (quantity sufficient to match active fill weight of 1920 mg per dose)
Change in Body Weight
Change from Baseline to Week 6 in body weight (kg) and percentage change in body weight, measured using a sponsor-provided Withings Scale (daily for three consecutive days at each timepoint; values averaged)
Time frame: Baseline to Week 6
Change in Waist Circumference
Change from Baseline to Week 6 in waist circumference (cm), measured using a sponsor-provided tape measure with CRC-guided instructions during a video call (three measurements taken and averaged)
Time frame: Baseline to Week 6
Change in BMI
Change from Baseline to Week 6 in BMI (kg/m²), calculated using weight measured by Withings Scale and self-reported height collected at Baseline
Time frame: Baseline to Week 6
Change in Self-Reported Appetite
Change from Baseline to Week 6 in self-reported appetite assessed using questionnaires including the Food Craving Questionnaire reduced (FCQ-T reduced), administered via the Citruslabs study platform
Time frame: Baseline to Week 6
Change in Self-Reported Between-Meal Hunger
Change from Baseline to Week 6 in between-meal hunger assessed using questionnaires including the Food Craving Questionnaire reduced (FCQ-T reduced), administered via the Citruslabs study platform
Time frame: Baseline to Week 6
Change in Self-Reported Post-Meal Fullness
Change from Baseline to Week 6 in post-meal fullness assessed using questionnaires including the Food Craving Questionnaire reduced (FCQ-T reduced), administered via the Citruslabs study platform
Time frame: Baseline to Week 6
Change in Perceived Control Over Eating
Change from Baseline to Week 6 in perceived control over eating assessed using questionnaires including the Food Craving Questionnaire reduced (FCQ-T reduced), administered via the Citruslabs study platform
Time frame: Baseline to Week 6
Change in Participant Perceptions of Effects on Appetite
Changes in participant-reported perceptions of the product's effect on appetite, assessed via self-reported questionnaire on the Citruslabs study platform
Time frame: Week 1 to Week 6
Change in Participant Perceptions of Effects on Satiety
Changes in participant-reported perceptions of the product's effect on satiety, assessed via self-reported questionnaire on the Citruslabs study platform
Time frame: Week 1 to Week 6
Change in Participant Perceptions of Effects on Eating Control
Changes in participant-reported perceptions of the product's effect on eating control, assessed via self-reported questionnaire on the Citruslabs study platform
Time frame: Week 1 to Week 6
Change in Participant Perceptions of Effects on Energy Levels
Changes in participant-reported perceptions of the product's effect on energy levels, assessed via self-reported questionnaire on the Citruslabs study platform
Time frame: Week 1 to Week 6
Change in Participant Perceptions of Overall Well-Being
Changes in participant-reported perceptions of the product's effect on overall well-being, assessed via self-reported questionnaire on the Citruslabs study platform
Time frame: Week 1 to Week 6
Incidence of Treatment-Emergent Adverse Events
Incidence, severity, and relatedness of treatment-emergent adverse events (TEAEs), collected via adverse event reporting through the study platform and direct participant communication
Time frame: Baseline through Week 6
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.